Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

BI-732

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Boehringer Ingelheim

Drug class:

EGFR inhibitor

Related drugs:

‹

cetuximab (347)

osimertinib (301)

erlotinib (235)

gefitinib (194)

panitumumab (123)

lapatinib (107)

neratinib (102)

brigatinib (50)

aumolertinib (39)

amivantamab-vmjw (25)

firmonertinib (14)

mobocertinib (12)

lazertinib (12)

tarloxotinib bromide (7)

nimotuzumab (6)

rociletinib (5)

tomuzotuximab (4)

necitumumab (3)

befotertinib (3)

zorifertinib (3)

ABP 494 (cetuximab biosimilar) (1)

BAY 2927088 (1)

Compound 6a (1)

abivertinib (1)

STI-001 (cetuximab biosimilar) (0)

antroquinonol (0)

zalutumumab (0)

JNJ-26483327 (0)

PF-08046052 (0)

rindopepimut (0)

Undisclosed EGFR inhibitor (0)

cetuximab biosimilar (0)

PF-06747775 (0)

JNJ-64041757 (0)

›

EGFR exon 19 deletion + EGFR C797S	Non Small Cell Lung Cancer	EGFR exon 19 deletion + EGFR C797S	Non Small Cell Lung Cancer	BI-732 Sensitive: D – Preclinical BI-732 Sensitive : D	BI-732 Sensitive: D – Preclinical BI-732 Sensitive : D
EGFR exon 19 deletion + EGFR T790M + EGFR C797S	Non Small Cell Lung Cancer	EGFR exon 19 deletion + EGFR T790M + EGFR C797S	Non Small Cell Lung Cancer	BI-732 Sensitive: D – Preclinical BI-732 Sensitive : D	BI-732 Sensitive: D – Preclinical BI-732 Sensitive : D